Skip to main page content
U.S. flag
See More

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2009 Oct;32(8):870-4.
doi: 10.1097/CJI.0b013e3181b36b69.

Impact of a recombinant fowlpox vaccine on the efficacy of adoptive cell therapy with tumor infiltrating lymphocytes in a patient with metastatic melanoma

Franz O Smith  1 , Jacob A Klapper, John R Wunderlich, Steven A Rosenberg, Mark E Dudley
Affiliations
Case Reports

Impact of a recombinant fowlpox vaccine on the efficacy of adoptive cell therapy with tumor infiltrating lymphocytes in a patient with metastatic melanoma

Franz O Smith et al. J Immunother. 2009 Oct.

Abstract

A patient with metastatic melanoma who had progressive disease after prior surgical resections, high dose interleukin-2, and anti-cytotoxic T lymphocyte antigen-4 antibody received sequential treatments with autologous tumor infiltrating lymphocytes that recognized the gp100 melanocyte differentiation antigen. Although no clinical response was seen when cells were administered alone, an objective clinical response to therapy was seen with tumor infiltrating lymphocytes administered together with a highly immunogenic fowlpox vaccine expressing a gp100: 209-217 (210M) epitope. Persistence of the transferred antigen-specific lymphocytes in the peripheral blood was observed only after adoptive cell therapy plus administration of vaccine. Cell proliferation in vitro was further stimulated by additional vaccine and interleukin-2. The patient has an ongoing partial response at 10 months after the last treatment.

PubMed Disclaimer

Conflict of interest statement

All authors have declared that there is no financial conflict of interest in regards to this work.

Figures

FIGURE 1.
FIGURE 1.
Clinical and immunologic impact of all treatments. A, Percentage of the gp209 tetramer-positive cells (percent of the total CD8 population) in the peripheral blood varies depending on the treatment administered. B, The longest diameters of the evaluable sites of disease is graphed versus time. LN indicates lymph node; Rx, treatment.
FIGURE 2.
FIGURE 2.
Clinical and immunologic impact of the third treatment. A, Persistence of antigen-reactive cells in the peripheral blood lymphocyte (PBL). B, Computed axial tomography of the evaluable lesions before treatment 3 and the maximum response (arrows indicate the sites of evaluable disease). Cy indicates cyclophosphamide; Flu, fludarabine; Fp, fowlpox; TIL, tumor infiltrating lymphocytes.
See this image and copyright information in PMC

References

    1. Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26:5233–5239. - PMC - PubMed
    1. Overwijk WW, Restifo NP. Autoimmunity and the immunotherapy of cancer: targeting the “self” to destroy the “other.” Crit Rev Immunol. 2000;20:433–450. - PMC - PubMed
    1. Overwijk WW, Theoret MR, Finkelstein SE, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med. 2003; 198:569–580. - PMC - PubMed
    1. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10:909–915. - PMC - PubMed
    1. Hsueh EC, Essner R, Foshag LJ, et al. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol. 2002;20:4549–4554. - PubMed

Publication types

MeSH terms